#None #BioLineRx #GLIX1 #Hemispherian

BioLineRx and Hemispherian Reach Important Milestone in Glioblastoma Treatment Trials

In a significant advancement in cancer treatment, BioLineRx Ltd. and Hemispherian AS have announced the dosing of the first patient in their groundbreaking Phase 1/2a clinical trial of GLIX1, targeting recurrent glioblastoma (GBM) and other high-grade gliomas. This trial, which signifies a pivotal moment in oncology, aims to explore innovative therapies for one of the most aggressive and treatment-resistant forms of cancer.

The patient received the treatment at NYU Langone Health, under the expert supervision of Dr. Alexandra Miller, a prominent figure in neuro-oncology and co-director of the Brain and Spine Tumor Center. This milestone is the result of a collaborative effort between BioLineRx and Hemispherian that was announced in September 2025.

Understanding GLIX1
GLIX1 is a first-in-class oral small molecule designed to activate TET2, thereby inducing tumor DNA damage specifically within cancer cells. This targeted approach aims to improve the response to treatment for glioblastoma, which has previously experienced stagnation in innovative therapies over the last two decades. The selection of GBM as the initial target for GLIX1 is based on its significantly suppressed TET2 activity and the considerable unmet medical need among patients.

Pre-clinical models, including in-vivo GBM studies, exhibited GLIX1’s promising anti-tumor activity, highlighting its ability to penetrate the blood-brain barrier effectively while maintaining a favorable safety profile. As the trial progresses, the data is poised to provide crucial insights that could pave the way for new therapeutic regimes.

Statements from Leaders in the Field
Philip Serlin, CEO of BioLineRx, expressed his optimism, stating, _“The dosing of the first patient in our Phase 1/2a study of GLIX1 is an important milestone for BioLineRx and, more importantly, for patients battling glioblastoma, a very challenging tumor where there has been very little innovation over the past 20 years.”_ He emphasized GLIX1’s potential not only for glioblastoma patients but also in broader applications across various cancer types where DNA damage repair is vital for tumor survival.

Zeno Albisser, CEO of Hemispherian, echoed this enthusiasm, commenting, _“The initiation of patient dosing in this important study represents a watershed event for Hemispherian and GLIX1. This is the culmination of years of focused scientific and operational work, and an important step toward bringing a new therapeutic approach to patients with glioblastoma.”_ He further expressed eagerness to gain initial clinical insights as the trial continues.

Clinical Trial Design and Objectives
The Phase 1 aspect of this trial is structured as a dose escalation study, with daily administration of GLIX1 to up to 30 patients suffering from recurrent and progressive GBM and other high-grade gliomas. The primary objective is to determine the maximum tolerated dose (MTD), and the results will help establish recommended dosages based on safety and preliminary efficacy. Initial data from this stage is expected to be available in the first half of 2027.

For the Phase 2a expansion, additional indications are planned, which will include newly diagnosed GBM and potentially other cancers, assessing the combined efficacy when used alongside standard treatments. This stage aims to collect valuable data on efficacy and dose optimization, forming a solid foundation for swift advancement in clinical development.

Looking Ahead
Hemispherian AS focuses on developing first-in-class small-molecule cancer therapies, with GLIX1 being at the forefront of its program. The company operates out of Oslo, Norway, collaborating with leading academic institutions worldwide. BioLineRx is similarly dedicated to advancing transformational therapies within oncology, with the ongoing clinical development of GLIX1 standing as a testament to its commitment.

The partnership’s collective vision is clear: remedy the stagnation faced by glioblastoma treatments and offer genuine hope to patients. As the study draws closer to its expected data release, the oncology community eagerly anticipates the outcomes that could redefine treatment landscapes for glioblastoma and beyond.